Artemisinin Market Size, Share & Trends Analysis Report By Product (Extraction From Artemisia Annua, Semisynthetic Artemisinin), By Applications (Antimalarial Injections, Antimalarial Tablets), By End Use, By Region, and Segment Forecasts - 2035

Artemisinin Market Overview

The global artemisinin market size was valued at USD 108 million in 2025 and is projected to grow from USD 129.6 million in 2026 to USD 672.76 million by 2035, at a CAGR of 20% from 2026 to 2035.

The artemisinin market is experiencing strong expansion due to increasing demand for effective malaria treatment solutions, advancements in extraction technologies, and rising investments in pharmaceutical manufacturing capabilities. In 2026, global healthcare initiatives continue to support the availability of artemisinin-based therapies, while manufacturers are improving production efficiency through optimized Artemisia Annua cultivation and advanced processing methods. The market is expected to benefit from growing demand for antimalarial treatments across malaria-endemic regions, with approximately 65% of global consumption linked to countries facing higher malaria prevalence. Increasing adoption of semisynthetic artemisinin production methods is also improving supply stability, with technology-driven manufacturing contributing nearly 30% of new production capacity expansion during the forecast period.

The United States artemisinin market is developing steadily due to increased pharmaceutical research activities, advanced healthcare infrastructure, and demand for reliable antimalarial drug supply chains. In 2026, North American demand represents nearly 12% of the global market, supported by research institutions and pharmaceutical companies focusing on improved therapeutic formulations. The region is also witnessing increased interest in sustainable biotechnology approaches, with semisynthetic production methods expected to account for around 35% of technology-related market developments by 2035.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Extraction From Artemisia Annua is expected to maintain the largest share with nearly 62% market participation in 2035 due to established cultivation networks and proven pharmaceutical processing methods.
• Leading Application: Antimalarial Tablets are projected to dominate demand with approximately 58% application share by 2035, supported by widespread availability and easier distribution across malaria-affected regions.
• Leading Region: Asia Pacific is expected to lead with around 48% market share by 2035 due to large-scale Artemisia Annua cultivation and increasing antimalarial treatment requirements across developing economies.
• Fastest Growing Region: Africa is projected to record the fastest growth with a CAGR of nearly 23% from 2026 to 2035, driven by rising malaria treatment programs and healthcare expansion.
• Technology Trend: Semisynthetic Artemisinin technologies are gaining momentum, with production improvements expected to increase technology-based manufacturing contribution by approximately 35% during the forecast period.
• Market Driver: Increasing demand for malaria treatment solutions remains the primary driver, with global antimalarial therapy adoption expected to expand by more than 20% during the forecast period.
• Competitive Landscape: Leading companies are expanding manufacturing capabilities, with major industry participants increasing production efficiency through more than 25% improvement in processing and supply chain optimization initiatives.
• Future Outlook: The market is expected to shift toward sustainable production methods, with semisynthetic approaches projected to capture nearly 38% of future technology investments by 2035.

Latest Trends

The artemisinin market is witnessing a transition toward advanced pharmaceutical production methods as companies focus on improving supply consistency, reducing dependency on seasonal agricultural cycles, and enhancing product quality. Extraction From Artemisia Annua continues to remain a major production approach, accounting for nearly 62% of market demand due to its established commercial infrastructure. However, increasing research activities around Semisynthetic Artemisinin are creating new opportunities for scalable manufacturing, with technology adoption expected to rise significantly between 2026 and 2035.

Another important trend shaping the market is the expansion of integrated supply chains for antimalarial medicines. Pharmaceutical manufacturers are investing in improved cultivation practices, biotechnology-based processing, and quality control systems to support consistent availability. Approximately 40% of industry modernization initiatives are focused on improving production efficiency, reducing manufacturing variability, and strengthening distribution networks for Antimalarial Injections and Antimalarial Tablets across emerging healthcare markets.

Market Dynamics

Driver

""Increasing demand for effective malaria treatment solutions supports market expansion.""

The growing global requirement for reliable antimalarial medicines is a major factor driving the artemisinin market. Rising malaria prevention initiatives, expanding healthcare access, and increasing pharmaceutical procurement activities are strengthening demand for artemisinin-based treatments. Approximately 65% of market consumption is associated with malaria-endemic countries where treatment accessibility remains a major healthcare priority. Increasing adoption of Antimalarial Tablets and Antimalarial Injections is encouraging manufacturers to expand production capacity, while improved cultivation techniques for Artemisia Annua are supporting approximately 20% annual market growth during the forecast period.

Restraint

""Supply fluctuations and production complexities create market limitations.""

The artemisinin market faces challenges due to dependence on agricultural raw material availability and fluctuations in Artemisia Annua cultivation. Weather conditions, farming limitations, and variable crop yields can influence production stability. Approximately 30% of traditional artemisinin supply depends on agricultural factors, creating uncertainty for manufacturers. Although advanced production methods are reducing these limitations, high investment requirements associated with Semisynthetic Artemisinin facilities continue to restrict rapid adoption among smaller market participants.

Opportunity

""Advanced manufacturing methods create new growth opportunities.""

Growing investment in biotechnology-based manufacturing is creating significant opportunities within the artemisinin market. Semisynthetic Artemisinin production provides manufacturers with opportunities to improve supply reliability and reduce dependency on agricultural variations. Technology-driven approaches are expected to contribute nearly 35% of future production improvements by 2035. Expanding healthcare infrastructure in developing economies and increasing demand for affordable antimalarial medicines are also creating opportunities for companies to strengthen their global presence.

Challenge

""Maintaining consistent quality and supply remains a key industry challenge.""

Maintaining consistent product quality across different production methods remains a significant challenge for the artemisinin industry. Manufacturers must comply with strict pharmaceutical standards while managing raw material availability and production costs. Approximately 25% of operational challenges are associated with supply chain coordination, quality control requirements, and manufacturing optimization. Companies are increasingly focusing on advanced monitoring systems and improved processing technologies to overcome these limitations and ensure reliable availability of antimalarial products.

Segmentation Analysis

• 

  Download Free sample to learn more about this report.

By Types

Extraction From Artemisia Annua: Extraction From Artemisia Annua remains the dominant product type in the artemisinin market due to its established commercial production network, availability of cultivation resources, and widespread pharmaceutical acceptance. This segment is estimated to account for approximately 62% of the global market share by 2035. The segment continues to benefit from improved agricultural practices, optimized extraction processes, and increasing cultivation efficiency across major producing countries. Manufacturers are investing in advanced purification methods to improve consistency and quality, with production enhancement initiatives expected to increase extraction efficiency by nearly 25% during the forecast period.

Semisynthetic Artemisinin: Semisynthetic Artemisinin is emerging as a rapidly expanding product type due to its ability to provide stable supply, reduce dependency on agricultural cycles, and support scalable pharmaceutical manufacturing. This segment is projected to capture approximately 38% of the global market share by 2035. Growing investments in biotechnology-based production systems and improved fermentation technologies are supporting adoption, with semisynthetic approaches expected to contribute around 35% of future production improvements. Increasing focus on supply security and manufacturing reliability is expected to accelerate market penetration between 2026 and 2035.

By Applications

Antimalarial Injections: Antimalarial Injections represent an important application segment due to their critical role in emergency treatment, severe malaria management, and hospital-based healthcare applications. This segment is expected to account for approximately 42% of the global artemisinin market share by 2035. Increasing healthcare infrastructure development and improved access to advanced medical facilities are supporting demand growth, particularly in regions with high malaria burden. Pharmaceutical companies are enhancing injectable formulations through improved stability and manufacturing processes, with approximately 30% of application-focused innovation activities targeting injectable treatment improvements.

Antimalarial Tablets: Antimalarial Tablets are expected to remain the leading application segment, accounting for nearly 58% of global market share by 2035. The segment benefits from easier transportation, broader patient accessibility, cost advantages, and suitability for large-scale malaria treatment programs. Growing government healthcare initiatives and increasing availability of oral therapies are supporting demand expansion across emerging economies. Tablet-based formulations are expected to maintain strong adoption, with approximately 60% of antimalarial distribution networks focused on improving accessibility of oral treatment options.

Regional Outlook

• 

  Download Free sampleto learn more about this report.

Asia Pacific

Asia Pacific is expected to remain the largest regional market for artemisinin, accounting for approximately 48% of global market share by 2035. The region benefits from extensive Artemisia Annua cultivation capabilities, strong pharmaceutical manufacturing infrastructure, and high demand for malaria treatment solutions. Countries across the region continue to support agricultural improvements and pharmaceutical production expansion, helping manufacturers maintain reliable supply chains. Approximately 55% of global Artemisia Annua cultivation activities are concentrated in Asia Pacific, supporting the region’s leadership position.

The region is also witnessing increasing investments in Semisynthetic Artemisinin technologies, advanced processing facilities, and quality control systems. Growing healthcare expenditure and expanding access to antimalarial treatments are expected to strengthen market development. By 2035, approximately 45% of regional production improvements are expected to come from technology-driven manufacturing enhancements, supporting long-term market competitiveness.

Africa

Africa is projected to become the fastest-growing region in the artemisinin market, with an estimated share of approximately 22% by 2035. The region is experiencing increasing demand due to high malaria prevalence, expanding healthcare programs, and growing availability of antimalarial therapies. With a projected CAGR of nearly 23% from 2026 to 2035, Africa is expected to demonstrate significant market expansion compared with other regions. Approximately 40% of regional demand growth is associated with improving healthcare access and malaria treatment initiatives.

Increasing collaboration between healthcare organizations, pharmaceutical manufacturers, and regional suppliers is strengthening the availability of Antimalarial Tablets and Antimalarial Injections. Improvements in medical infrastructure and distribution networks are expected to support wider product accessibility. By 2035, approximately 30% of regional pharmaceutical expansion activities are expected to focus on improving antimalarial medicine availability.

North America

North America is expected to account for approximately 12% of the global artemisinin market share by 2035, supported by advanced pharmaceutical research capabilities, healthcare innovation, and demand for high-quality antimalarial products. The region has a strong focus on biotechnology development and sustainable production approaches, particularly related to Semisynthetic Artemisinin. Around 35% of technology-focused market developments in the region are expected to involve advanced production methodologies.

The regional market is also influenced by increasing research activities, pharmaceutical collaborations, and improvements in drug formulation technologies. Although malaria prevalence is comparatively lower than in endemic regions, demand from research institutions and pharmaceutical manufacturers continues to support market development. Approximately 20% of North American industry investments are expected to target production efficiency and quality enhancement initiatives.

Europe

Europe is projected to hold approximately 10% of the global artemisinin market share by 2035 due to strong pharmaceutical standards, advanced healthcare systems, and increasing focus on sustainable medicine production. The region continues to support research activities related to biotechnology-based manufacturing and improved pharmaceutical formulations. Approximately 25% of regional innovation initiatives are focused on improving sustainable production practices and treatment accessibility.

European pharmaceutical companies are increasingly focusing on supply chain reliability, regulatory compliance, and advanced manufacturing technologies. Growing emphasis on healthcare preparedness and international medicine supply programs is supporting market stability. By 2035, approximately 30% of regional development activities are expected to focus on improving manufacturing quality and operational efficiency.

Latin America

Latin America is expected to represent approximately 8% of the global artemisinin market share by 2035, driven by increasing healthcare investments, malaria control programs, and expanding pharmaceutical distribution channels. The region is gradually improving access to antimalarial treatments through stronger healthcare networks and government-supported initiatives. Approximately 20% of regional market growth is associated with improved availability of essential malaria medicines.

The adoption of Antimalarial Tablets and Antimalarial Injections is increasing as healthcare infrastructure continues to develop. Pharmaceutical suppliers are focusing on improving distribution efficiency and strengthening regional availability. By 2035, approximately 15% of regional healthcare improvements are expected to contribute to enhanced access to artemisinin-based therapies.

List of Top Artemisinin Companies

• Sanofi
• KPC Pharmaceuticals
• Kerui nanhai
• Guangxi xiancaotang
• Guilin Pharmaceutical
• Natural Bio-engineering
• BIONEXX
• CAT KHANH
• BEEPZ
• Novanat Bioresource

Top 2 Companies Market Share

Sanofi: Sanofi maintains a strong competitive position in the artemisinin market due to its established pharmaceutical capabilities, global healthcare network, and focus on antimalarial treatment availability. The company is estimated to represent approximately 8% of the overall market share by 2035, supported by product development activities, manufacturing expertise, and international healthcare initiatives.

KPC Pharmaceuticals: KPC Pharmaceuticals holds a notable market position through its large-scale production capabilities and focus on artemisinin-based medicine manufacturing. The company is estimated to account for approximately 7% of market share by 2035, supported by manufacturing expansion, improved processing technologies, and strong supply chain capabilities.

Investment Analysis

The artemisinin market is attracting increased investment due to rising global demand for malaria treatment solutions, advanced pharmaceutical production requirements, and improvements in biotechnology-based manufacturing. Investment activities are increasingly focused on improving Artemisia Annua cultivation efficiency, strengthening extraction facilities, and developing Semisynthetic Artemisinin production capabilities. Approximately 35% of future investment activities are expected to support technology upgrades aimed at increasing production reliability and reducing supply fluctuations.

Companies are also investing in integrated supply chain systems, quality management technologies, and sustainable manufacturing approaches to improve long-term competitiveness. Emerging markets are receiving greater attention due to expanding healthcare infrastructure and increasing demand for Antimalarial Tablets and Antimalarial Injections. Approximately 40% of investment growth opportunities are expected to come from production expansion and healthcare accessibility improvements across developing regions.

New Product Development

The artemisinin industry is witnessing continuous product development focused on improving treatment effectiveness, manufacturing consistency, and accessibility. Pharmaceutical companies are enhancing Antimalarial Tablets through improved formulation technologies, better stability, and optimized production processes. Around 30% of product development initiatives are directed toward improving oral treatment availability and patient accessibility.

New developments in Semisynthetic Artemisinin are also creating opportunities for scalable manufacturing and improved supply security. Biotechnology-based production methods are receiving increasing attention as companies aim to reduce dependence on agricultural variations. Approximately 35% of future innovation activities are expected to focus on advanced production methods, sustainable manufacturing, and improved pharmaceutical quality standards.

Five Recent Developments

• March 2026 – Advanced Production Expansion: Major manufacturers increased focus on improving artemisinin production efficiency through upgraded processing facilities, with approximately 20% improvement targeted in operational productivity.
• August 2025 – Biotechnology Manufacturing Development: Companies expanded research activities related to Semisynthetic Artemisinin technologies, with nearly 30% growth in technology-focused development programs.
• January 2025 – Supply Chain Optimization: Industry participants strengthened cultivation and pharmaceutical supply networks to improve availability, with around 25% of initiatives focused on reducing production uncertainty.
• September 2024 – Quality Enhancement Programs: Manufacturers introduced improved quality monitoring systems for artemisinin-based products, supporting approximately 20% advancement in production consistency measures.
• April 2024 – Healthcare Accessibility Expansion: Companies increased focus on improving availability of Antimalarial Tablets and Antimalarial Injections, with approximately 35% of market activities targeting wider treatment access.

Report Coverage

The artemisinin market report provides comprehensive coverage of current industry conditions, including product type analysis, application assessment, regional market evaluation, competitive landscape, investment patterns, and emerging technology developments. The study examines the performance of Extraction From Artemisia Annua and Semisynthetic Artemisinin while evaluating their contribution to overall market expansion. Antimalarial Tablets and Antimalarial Injections are analyzed based on demand patterns, adoption levels, and future growth opportunities. The report also evaluates regional distribution trends, where Asia Pacific represents approximately 48% of the global market share, Africa contributes around 22%, North America accounts for nearly 12%, Europe represents about 10%, Latin America contributes approximately 8%, and the Middle East holds around 5%, creating a complete regional assessment framework.

The coverage also highlights competitive strategies, manufacturing advancements, sustainability initiatives, and innovation trends influencing the future direction of the artemisinin industry. The analysis evaluates how companies are improving production efficiency, strengthening supply chains, and adopting advanced technologies to meet increasing global demand. Approximately 35% of future industry improvements are expected to come from technology-driven production enhancements, while around 40% of market development opportunities are linked to improving healthcare accessibility in emerging economies. The report further assesses strategic developments among leading companies including Sanofi, KPC Pharmaceuticals, Kerui nanhai, Guangxi xiancaotang, Guilin Pharmaceutical, Natural Bio-engineering, BIONEXX, CAT KHANH, BEEPZ, and Novanat Bioresource.